| scholarly article | Q13442814 |
| P2093 | author name string | Li Wang | |
| Constance T Noguchi | |||
| Ruifeng Teng | |||
| Mawadda Alnaeeli | |||
| Amanda Foskett | |||
| P2860 | cites work | Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. | Q53204531 |
| Tumor necrosis factor-alpha prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells | Q70589814 | ||
| Correction of anemia with epoetin alfa in chronic kidney disease | Q79363020 | ||
| Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance | Q83864443 | ||
| Inflammation and insulin resistance | Q22241893 | ||
| Epidemiologic and economic consequences of the global epidemics of obesity and diabetes | Q22251061 | ||
| Inflammation and metabolic disorders | Q27860923 | ||
| Erythropoietin receptor signalling is required for normal brain development | Q28507560 | ||
| Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo | Q28594830 | ||
| Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles | Q33466769 | ||
| American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer | Q33727562 | ||
| A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment | Q33985849 | ||
| Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency | Q35865066 | ||
| A novel protective effect of erythropoietin in the infarcted heart | Q36001255 | ||
| In vivo evidence that erythropoietin protects neurons from ischemic damage | Q36477827 | ||
| Insulin sensitivity: modulation by nutrients and inflammation | Q36848937 | ||
| Obesity, inflammation, and atherosclerosis | Q37462172 | ||
| Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis | Q37506973 | ||
| TNF-alpha, a potent lipid metabolism regulator | Q37598164 | ||
| Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice | Q37601187 | ||
| Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models | Q38347353 | ||
| Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function | Q39126733 | ||
| The role of erythropoietin in regulating angiogenesis | Q40494744 | ||
| Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer | Q40613603 | ||
| Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. | Q40854129 | ||
| Inactivation of erythropoietin leads to defects in cardiac morphogenesis | Q41679719 | ||
| A potential role for erythropoietin in focal permanent cerebral ischemia in mice. | Q42473313 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | obesity | Q12174 |
| erythropoietin | Q218706 | ||
| P304 | page(s) | 373781 | |
| P577 | publication date | 2011-04-20 | |
| P1433 | published in | Journal of Biomedicine and Biotechnology | Q15752146 |
| P1476 | title | The effects of erythropoietin dose titration during high-fat diet-induced obesity | |
| P478 | volume | 2011 |
| Q57494887 | Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice |
| Q36353576 | Erythropoietin alleviates hepatic insulin resistance via PPARγ-dependent AKT activation |
| Q35834761 | Erythropoietin and obesity-induced white adipose tissue inflammation: redefining the boundaries of the immunometabolism territory |
| Q36933740 | Erythropoietin contributes to slow oxidative muscle fiber specification via PGC-1α and AMPK activation |
| Q39377594 | Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo. |
| Q86492182 | Erythropoietin enhances whole body lipid oxidation during prolonged exercise in humans |
| Q42850017 | Erythropoietin has a restorative effect on the contractility of arteries following experimental hypoxia |
| Q35909929 | Erythropoietin in brain development and beyond |
| Q91015233 | Erythropoietin modulates bone marrow stromal cell differentiation |
| Q35306172 | Erythropoietin negatively regulates pituitary ACTH secretion |
| Q36406766 | Erythropoietin regulates POMC expression via STAT3 and potentiates leptin response |
| Q33789378 | Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity |
| Q36150300 | Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance |
| Q89580572 | Regulation of muscle and metabolic physiology by hypothalamic erythropoietin independently of its peripheral action |
| Q38914052 | Sex difference in mouse metabolic response to erythropoietin |
| Q89802108 | Sex-specific brain erythropoietin regulation of mouse metabolism and hypothalamic inflammation |
| Q89620015 | The Many Facets of Erythropoietin Physiologic and Metabolic Response |
| Q50510341 | Three weeks of erythropoietin treatment hampers skeletal muscle mitochondrial biogenesis in rats. |
Search more.